Genfit S.A.
Index- P/E4.24 EPS (ttm)1.10 Insider Own- Shs Outstand51.45M Perf Week0.86%
Market Cap240.79M Forward P/E- EPS next Y- Insider Trans- Shs Float43.23M Perf Month23.16%
Income69.40M PEG- EPS next Q- Inst Own4.20% Short Float0.69% Perf Quarter42.25%
Sales88.30M P/S2.73 EPS this Y146.40% Inst Trans-0.60% Short Ratio9.80 Perf Half Y14.71%
Book/sh0.71 P/B6.56 EPS next Y- ROA- Target Price8.48 Perf Year23.16%
Cash/sh4.45 P/C1.05 EPS next 5Y- ROE- 52W Range3.01 - 6.38 Perf YTD-6.40%
Dividend- P/FCF- EPS past 5Y29.40% ROI34.30% 52W High-28.21% Beta1.50
Dividend %- Quick Ratio- Sales past 5Y66.10% Gross Margin98.30% 52W Low52.16% ATR0.33
Employees112 Current Ratio- Sales Q/Q2810.40% Oper. Margin- RSI (14)59.98 Volatility7.12% 7.22%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume2.16 Prev Close4.68
ShortableYes LT Debt/Eq- EarningsMay 11 AMC Payout- Avg Volume30.24K Price4.58
Recom- SMA204.10% SMA5018.64% SMA20018.26% Volume30,741 Change-2.14%
Dec-20-21Upgrade H.C. Wainwright Neutral → Buy $8
Jul-23-20Upgrade Stifel Hold → Buy
Jun-25-20Initiated BofA/Merrill Underperform $7
May-13-20Downgrade Kepler Buy → Reduce
May-12-20Downgrade H.C. Wainwright Buy → Neutral $46 → $11
May-12-20Downgrade Barclays Overweight → Equal Weight $55 → $14
Oct-29-19Reiterated B. Riley FBR Buy $52 → $43
Jun-25-19Initiated Stifel Hold
Apr-24-19Initiated SVB Leerink Outperform $58
Apr-22-19Initiated Barclays Overweight
Jul-08-22 04:10PM  
May-25-22 04:10PM  
May-11-22 04:10PM  
Apr-29-22 04:10PM  
Apr-20-22 04:10PM  
Apr-14-22 12:00PM  
Apr-07-22 04:10PM  
Feb-28-22 04:10PM  
Jan-24-22 04:10PM  
Jan-21-22 04:10PM  
Jan-11-22 10:00AM  
Dec-23-21 10:00AM  
Dec-17-21 11:42AM  
Nov-18-21 04:15PM  
Nov-09-21 04:10PM  
Nov-08-21 04:10PM  
Nov-02-21 05:10PM  
Sep-29-21 04:10PM  
Jul-09-21 04:10PM  
Jun-30-21 04:10PM  
Jun-24-21 04:10PM  
Jun-23-21 04:10PM  
Jun-18-21 12:52PM  
Jun-15-21 04:10PM  
May-27-21 04:10PM  
May-12-21 04:10PM  
May-11-21 04:10PM  
May-10-21 04:10PM  
May-03-21 02:10AM  
Apr-23-21 12:30PM  
Apr-22-21 04:10PM  
Apr-01-21 04:10PM  
Mar-04-21 04:10PM  
Mar-01-21 04:05PM  
Feb-26-21 04:10PM  
Feb-23-21 10:50AM  
Feb-22-21 04:10PM  
Feb-18-21 05:00PM  
Feb-12-21 05:00PM  
Feb-10-21 04:10PM  
Feb-09-21 04:10PM  
Jan-28-21 04:10PM  
Jan-27-21 03:30PM  
Jan-25-21 01:30PM  
Jan-13-21 04:15PM  
Jan-12-21 02:15PM  
Jan-11-21 04:10PM  
Jan-08-21 12:30PM  
Jan-06-21 04:10PM  
Dec-23-20 03:11PM  
Dec-22-20 07:38PM  
Dec-07-20 02:10AM  
Nov-30-20 02:10AM  
Nov-23-20 02:15AM  
Nov-16-20 04:10PM  
Sep-30-20 04:05PM  
Sep-28-20 02:00AM  
Sep-25-20 07:37AM  
Sep-24-20 04:10PM  
Sep-22-20 04:10PM  
Sep-02-20 11:20AM  
Aug-26-20 04:10PM  
Aug-05-20 07:35AM  
Jul-23-20 11:02AM  
Jul-22-20 04:05PM  
Jul-10-20 04:05PM  
Jun-30-20 10:29AM  
Jun-29-20 04:05PM  
Jun-15-20 05:19PM  
Jun-10-20 08:36AM  
May-26-20 01:19PM  
May-14-20 05:31PM  
May-12-20 02:20PM  
May-11-20 05:52PM  
Apr-17-20 08:43AM  
Apr-11-20 02:32AM  
Mar-30-20 06:06PM  
Mar-04-20 04:26PM  
Mar-03-20 02:20PM  
Mar-02-20 05:35PM  
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.